ADAR1 Capital Management »

Fibrogen shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Fibrogen (FGEN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Fibrogen

Tip: Access up to 7 years of quarterly data

All positions including Fibrogen held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fibrogen by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $50k 21k 2.35

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Fibrogen

PRIMECAP Management Company
Armistice Capital
BlackRock
Vanguard Group
Acadian Asset Management
Citadel Advisors
Jacobs Levy Equity Management
Geode Capital Management
683 Capital Management
Two Sigma Advisers
Point72 Asset Management
Two Sigma Investments
Pennant Investors
Northern Trust
AQR Capital Management

View all funds holding Fibrogen